Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Malignant Lymphoma

Free Subscription Articles published in Haematologica Retrieve available abstracts of 235 articles: HTML format

Single Articles

July 2026
1. JIN Y, Fang Y, Yao Y
   Separating dose schedule from disease biology in CD19 CAR T-cell therapy. Comment on: "A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin
   Haematologica. 2026 Jul 23. doi: 10.3324/haematol.2026.301607.
   PubMed     Abstract available
   
   
   
2. DAY JR, Ansell SM
   Safety, feasibility, and efficacy of anti-PD-1 therapy for the treatment of classical Hodgkin lymphoma.
   Haematologica. 2026 Jul 23. doi: 10.3324/haematol.2026.301267.
   PubMed     Abstract available
   
   
   
3. ILLIDGE T, Wilson W, Paterson J, Bates A, et al
   Final results of UK NCRI phase II trial of pembrolizumab and radiotherapy in cutaneous T cell lymphoma.
   Haematologica. 2026 Jul 23. doi: 10.3324/haematol.2025.288878.
   PubMed     Abstract available
   
   
   
4. JOHANSSON A, Nilsson D, Wikstrom F, Olsson LM, et al
   Integrated spatially guided transcriptomics and multiplex imaging identify a high-risk CD163+/CD11c-subgroup in diffuse large B-cell lymphoma.
   Haematologica. 2026 Jul 23. doi: 10.3324/haematol.2025.300429.
   PubMed     Abstract available
   
   
   
5. WANG W, Liu D, Wei H, Wang H, et al
   Comprehensive evaluation of safety and efficacy: TEAM versus BEAM as conditioning for autologous transplantation in patients with lymphoma.
   Haematologica. 2026 Jul 23. doi: 10.3324/haematol.2026.301018.
   PubMed     Abstract available
   
   
   
6. EICHENAUER DA, Buhnen I, Basaran A, Fuchs M, et al
   Comparison and combination of prognostic scores for nodular lymphocytepredominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group.
   Haematologica. 2026 Jul 16. doi: 10.3324/haematol.2026.300633.
   PubMed     Abstract available
   
   
   
7. YLSTRA B, Groenen PJTA, Los-de Vries T, Janssen J, et al
   Enteropathy-associated T-cell lymphoma: molecular clonal evolution and its clinical consequences.
   Haematologica. 2026 Jul 16. doi: 10.3324/haematol.2026.300770.
   PubMed     Abstract available
   
   
   
8. DLOUHY I, Maia T, Viegas D, Abreu N, et al
   Notable clinical activity of immune checkpoint inhibitors with or without brentuximab vedotin in relapsed or refractory gray zone lymphoma.
   Haematologica. 2026 Jul 16. doi: 10.3324/haematol.2026.301128.
   PubMed     Abstract available
   
   
   
9. GALTIER J, Basile G, Bouabdallah K
   Response to comment on: "Brentuximab-vedotin and bendamustine for relapsed or refractory Hodgkin lymphoma: the LYSA real-world experience".
   Haematologica. 2026 Jul 9. doi: 10.3324/haematol.2026.301477.
   PubMed     Abstract available
   
   
   
10. TADMOR T
    A ray of hope for early-stage T-cell lymphoma.
    Haematologica. 2026 Jul 9. doi: 10.3324/haematol.2026.301390.
    PubMed     Abstract available
    
    
    
11. LI R, Sheng L, Ma J, Lu X, et al
    Dual resistance to asparaginase and PD-1 blockade in extranodal natural killer/T-cell lymphoma: dismal outcomes from a multicenter cohort.
    Haematologica. 2026 Jul 9. doi: 10.3324/haematol.2026.300670.
    PubMed     Abstract available
    
    
    
12. ORTIZ-MALDONADO V, Liang EC, Huang JJ, Jeon Y, et al
    A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma.
    Haematologica. 2026 Jul 2. doi: 10.3324/haematol.2025.300321.
    PubMed     Abstract available
    
    
    
13. BEHMAN J, Ahmed N, Hashmi S, Aljurf M, et al
    Female sex is associated with superior outcomes in patients treated with CD19-directed CAR T-cell therapy for large B-cell lymphoma.
    Haematologica. 2026 Jul 2. doi: 10.3324/haematol.2026.300993.
    PubMed     Abstract available
    
    
    
14. SCHROERS-MARTIN JG, Merryman R, Spinner MA, Yeung A, et al
    Anti-CD47 antibody magrolimab with pembrolizumab in patients with relapsed / refractory classic Hodgkin lymphoma.
    Haematologica. 2026 Jul 2. doi: 10.3324/haematol.2026.300899.
    PubMed     Abstract available
    
    
    June 2026
15. NAOI Y, Chijimatsu R, Urata T, Sunami K, et al
    Gradient of CD79B expression in diffuse large B-cell lymphoma corresponds to stages of germinal center B-cell differentiation.
    Haematologica. 2026 Jun 25. doi: 10.3324/haematol.2025.300248.
    PubMed     Abstract available
    
    
    
16. GIORDANO C, Picardi M
    Early Intensification with bendamustine supercharge plus brentuximab vedotinfollowing failure to obtain complete metabolic remission after two cycles of ABVD inpatients aged
    Haematologica. 2026 Jun 18. doi: 10.3324/haematol.2026.301273.
    PubMed     Abstract available
    
    
    
17. DONG S, Wang M, Luo Z, Wu W, et al
    Glofitamab plus polatuzumab vedotin: a novel safe, and highly effective chemotherapy-free regimen for pediatric relapsed/refractory B-cell non-Hodgkin lymphoma.
    Haematologica. 2026 Jun 18. doi: 10.3324/haematol.2026.300836.
    PubMed     Abstract available
    
    
    
18. LEE JY, Kim SA, Yang DH, Eum HS, et al
    Phase II study of lenalidomide maintenance after rituximab-methotrexatebased induction therapy in primary central nervous system lymphoma.
    Haematologica. 2026 Jun 18. doi: 10.3324/haematol.2026.300790.
    PubMed     Abstract available
    
    
    
19. STANCHINA MD, Alderuccio JP
    T-cell engagement in practice: bispecifics in large B-cell lymphoma.
    Haematologica. 2026 Jun 11. doi: 10.3324/haematol.2026.301265.
    PubMed     Abstract available
    
    
    
20. GUIRAUD V, Bravetti C, Guihot A, Denis JA, et al
    Clonal expansion of CAR-T cells harboring lentivector integration in the PLAAT4 gene following anti-CD19 CAR T-cell therapy in a context of cutaneous T-cell lymphoma.
    Haematologica. 2026 Jun 11. doi: 10.3324/haematol.2026.300851.
    PubMed     Abstract available
    
    
    
21. STUVER R, Moore ZR, Barta SK, Bhansali RS, et al
    Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patterns.
    Haematologica. 2026 Jun 11. doi: 10.3324/haematol.2026.300853.
    PubMed     Abstract available
    
    
    
22. WEI C, Zhao D, Jia C, Shen K, et al
    Cytotoxic T-cell lymphoma with muscle involvement and germline variants in inborn error of immunity-related genes: clinical and genetic insights from a case series.
    Haematologica. 2026 Jun 4. doi: 10.3324/haematol.2026.300669.
    PubMed     Abstract available
    
    
    
23. NOERENBERG D
    The gap narrows but shifts. Response to Comment on: "Mind the gap: anti-PD-1 salvage before autologous transplantation in classical Hodgkin lymphoma".
    Haematologica. 2026 Jun 4. doi: 10.3324/haematol.2026.301293.
    PubMed     Abstract available
    
    
    May 2026
24. BOUSSI L, Ovalle NT, Imber BS, Ewalt MD, et al
    Lorlatinib-induced remission in refractory acute myeloid leukemia with an anaplastic lymphoma kinase fusion.
    Haematologica. 2026 May 28. doi: 10.3324/haematol.2026.300893.
    PubMed     Abstract available
    
    
    
25. THARMASEELAN H, Von Tresckow B
    On closing the gap: anti-PD-1-based salvage in relapsed/refractory classical Hodgkin lymphoma. Comment on: "Mind the gap: anti-PD-1 salvage before autologous transplantation in classical Hodgkin lymphoma".
    Haematologica. 2026 May 28. doi: 10.3324/haematol.2026.301234.
    PubMed     Abstract available
    
    
    
26. DANN EJ
    Response to Comment on: "Is it time to reduce the doxorubicin dosage in Hodgkin lymphoma therapy?".
    Haematologica. 2026 May 28. doi: 10.3324/haematol.2026.301249.
    PubMed     Abstract available
    
    
    
27. LAZAROVICI J, Amorim S, Bouabdallah K, Fournier M, et al
    Nivolumab with or without vinblastine for first-line treatment of elderly patients with Hodgkin lymphoma and coexisting medical conditions: the Niviniho phase II Lysa study.
    Haematologica. 2026 May 28. doi: 10.3324/haematol.2025.300166.
    PubMed     Abstract available
    
    
    
28. AHEARNE MJ
    An epigenetic Achilles' heel in extranodal NK/T-cell lymphoma?
    Haematologica. 2026 May 21. doi: 10.3324/haematol.2026.301083.
    PubMed     Abstract available
    
    
    
29. SESQUES P, Houot R, Al Tabaa Y, Le Bras F, et al
    Prolonged survival with glofitamab in non-diffuse large B-cell lymphoma after CAR T-cell therapy relapse.
    Haematologica. 2026 May 21. doi: 10.3324/haematol.2026.300537.
    PubMed     Abstract available
    
    
    
30. OSBORNE W, Haynes E, Wilson W, Ediriwickrema K, et al
    Glofitamab and epcoritamab for large B cell lymphoma: a real-world retrospective UK analysis of efficacy, tolerability, and impact of treatment sequencing.
    Haematologica. 2026 May 14. doi: 10.3324/haematol.2026.300569.
    PubMed     Abstract available
    
    
    
31. GADDIPATI P, Ayad A, Epstein-Peterson Z, Palomba ML, et al
    CD20 re-emergence in a patient with diffuse large b-cell lymphoma who experienced a CD20-negative relapse after glofitamab treatment.
    Haematologica. 2026 May 14. doi: 10.3324/haematol.2025.300182.
    PubMed     Abstract available
    
    
    
32. AKKAD N, Jeffe DB, Krause A, Al-Hammadi N, et al
    The development and preliminary validation of the CTCL-PRO-20: a novel quality of life survey for patients with cutaneous T-cell lymphoma.
    Haematologica. 2026 May 7. doi: 10.3324/haematol.2025.300426.
    PubMed     Abstract available
    
    
    
33. PICARDI M, Vincenzi A
    Is it time to increase the liposomal doxorubicin dosage for frontline therapy in young adults and adults with classic Hodgkin lymphoma? Comment on: "Is it time to reduce the doxorubicin dosage in Hodgkin lymphoma therapy?".
    Haematologica. 2026 May 7. doi: 10.3324/haematol.2026.301044.
    PubMed     Abstract available
    
    
    
34. KIKUCHI S, Negoro E, Horaguchi R, Fujihira T, et al
    Optimizing bone health in lymphoma survivors: denosumab superiority to alendronate for R-CHOP-like therapy (the DENOSULY phase III randomized controlled trial).
    Haematologica. 2026 May 7. doi: 10.3324/haematol.2026.300564.
    PubMed     Abstract available
    
    
    
35. LOYAUX R, Chraibi S, Pesic M, Debus L, et al
    SWI/SNF alterations define a subgroup with poorer outcome among patients with aggressive forms of adult T-cell leukemia/lymphoma.
    Haematologica. 2026 May 7. doi: 10.3324/haematol.2026.300706.
    PubMed     Abstract available
    
    
    April 2026
36. LUTTERBECK C, Kaufman D, Bolen CR, Shin M, et al
    Circulating tumor DNA at baseline as a prognostic marker in untreated follicular lymphoma.
    Haematologica. 2026 Apr 23. doi: 10.3324/haematol.2025.289111.
    PubMed     Abstract available
    
    
    
37. BASILE G, Neuville A, Martineau D, Delapierre B, et al
    Brentuximab-vedotin and bendamustine for relapsed or refractory Hodgkin lymphoma: the LYSA real-world experience.
    Haematologica. 2026 Apr 23. doi: 10.3324/haematol.2025.300289.
    PubMed     Abstract available
    
    
    
38. PAGES-GELI C, Medina-Gil D, Fernandez-Guzman P, Hernandez C, et al
    Immune evasion in primary central nervous system lymphoma: macrophage and T cell roles in response to immunotherapy.
    Haematologica. 2026 Apr 23. doi: 10.3324/haematol.2025.300015.
    PubMed     Abstract available
    
    
    
39. KERSTEN MJ, Dreyling M, Linton KM, Chitu D, et al
    Lenalidomide-rituximab or lenalidomide-rituximab-bendamustine for relapsed/refractory follicular lymphoma: primary and final analysis of the randomized phase II HOVON110/ReBeL study.
    Haematologica. 2026 Apr 16. doi: 10.3324/haematol.2025.300152.
    PubMed     Abstract available
    
    
    
40. MIYAGI S, Mori K, Miyawaki K, Shimo M, et al
    Gene expression profile of adult T-cell leukemia/lymphoma with human T-cell lymphotropic virus type 1-infected Hodgkin and Reed-Sternberg-like cells is more similar to classic Hodgkin lymphoma than typical adult T-cell leukemia/lymphoma.
    Haematologica. 2026 Apr 16. doi: 10.3324/haematol.2025.289270.
    PubMed     Abstract available
    
    
    
41. POTT C
    Relapse as a return, not a reinvention - genomic stability and pre-existing resistance in mantle cell lymphoma.
    Haematologica. 2026 Apr 9. doi: 10.3324/haematol.2025.289129.
    PubMed     Abstract available
    
    
    
42. ANDRE A, Bourbon E, Cartron G, Morschhauser F, et al
    Anti-CD19 CAR T-cell therapy in relapsed/refractory T-cell/histiocyte-rich large B-cell lymphoma: insights from the French DESCAR-T registry, a LYSA study.
    Haematologica. 2026 Apr 9. doi: 10.3324/haematol.2025.289196.
    PubMed     Abstract available
    
    
    
43. SHUMILOV E, Wurm-Kuczera R, Kauer J, Wang M, et al
    Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell lymphoma.
    Haematologica. 2026 Apr 2. doi: 10.3324/haematol.2025.300063.
    PubMed     Abstract available
    
    
    
44. ILAN U, Boer JM, Luesink M, Bautista F, et al
    First-year results of the International Leukemia/Lymphoma Target Board for pediatric relapsed and refractory hematological malignancies.
    Haematologica. 2026 Apr 2. doi: 10.3324/haematol.2025.300154.
    PubMed     Abstract available
    
    
    
45. ORTIZ CR, Abouzeid H, De Bernardi C, Durham A, et al
    Azacitidine-induced remission enables allogeneic transplantation in TET2/BCOR-mutant relapsed extranodal natural killer/T-cell lymphoma: a case report.
    Haematologica. 2026 Apr 2. doi: 10.3324/haematol.2025.300314.
    PubMed     Abstract available
    
    
    
46. HWANG A, Kirkwood AA, Hardefeldt P, Amrith M, et al
    CAR-T therapy for relapsed/refractory large B-cell lymphoma in people living with HIV: efficacy, toxicity and treatment considerations.
    Haematologica. 2026 Apr 2. doi: 10.3324/haematol.2025.300151.
    PubMed     Abstract available
    
    
    
47. ABEYAKOON C, Kuruvilla J
    Relapsed classic Hodgkin lymphoma; should all patients receive an autologous stem cell transplant? - the PRO.
    Haematologica. 2026 Apr 2. doi: 10.3324/haematol.2026.300574.
    PubMed     Abstract available
    
    
    March 2026
48. TEMBRINK M, Haverkamp T, Reinhardt HC, Hanoun M, et al
    Peripheral T-cell lymphoma in adult-onset familial hemophagocytic lymphohistiocytosis type 2 and heterozygous LRBA mutation.
    Haematologica. 2026 Mar 19. doi: 10.3324/haematol.2026.300514.
    PubMed     Abstract available
    
    
    
49. RAMDIAL J, Agbadiba E, Hawkins M, Ayers A, et al
    Salvage high-dose chemotherapy and autologous stem cell transplant consolidation following relapse after CAR-T cell for large B-cell lymphoma.
    Haematologica. 2026 Mar 19. doi: 10.3324/haematol.2025.300402.
    PubMed     Abstract available
    
    
    
50. SUNDER-PLASSMANN V, Kiesewetter B, Simonitsch-Klupp I, Brand R, et al
    Histological response dynamics in gastric extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue after helicobacter-pylori eradication: a singlecenter longitudinal analysis.
    Haematologica. 2026 Mar 19. doi: 10.3324/haematol.2025.300054.
    PubMed     Abstract available
    
    
    
51. STUVER R, Tang H, Dogan A, Epstein-Peterson ZD, et al
    Non-JAK-family gene fusions in cutaneous T-cell lymphoma highlights genetic diversity and potential therapeutic targets.
    Haematologica. 2026 Mar 19. doi: 10.3324/haematol.2025.300064.
    PubMed     Abstract available
    
    
    
52. PICARDI M, Vincenzi A
    Systematic echocardiogram surveillance to early detect and treat doxorubicin hydrochloride-induced cardiomyopathy in young adults and adults with classical Hodgkin lymphoma. Comment on: Long-term cardiac morbidity in adolescent and young adult survivo
    Haematologica. 2026 Mar 12. doi: 10.3324/haematol.2025.300167.
    PubMed     Abstract available
    
    
    
53. RUSSLER-GERMAIN DA, Bartlett NL
    To B or not to B, that is the question: the role of bleomycin in early stage Hodgkin lymphoma.
    Haematologica. 2026 Mar 12. doi: 10.3324/haematol.2026.300832.
    PubMed     Abstract available
    
    
    
54. NOERENBERG D
    Mind the gap: anti-PD-1 salvage before autologous transplantation in classical Hodgkin lymphoma.
    Haematologica. 2026 Mar 12. doi: 10.3324/haematol.2026.300488.
    PubMed     Abstract available
    
    
    
55. AVIVI I
    Unmasking the invisible: CAR T-cell therapy for intravascular large B-cell lymphoma.
    Haematologica. 2026 Mar 12. doi: 10.3324/haematol.2026.300761.
    PubMed     Abstract available
    
    
    
56. TALAMI A, Nizzoli ME, Cappello E, Luminari S, et al
    Prognosis in marginal zone lymphoma: a comprehensive review.
    Haematologica. 2026 Mar 5. doi: 10.3324/haematol.2025.300416.
    PubMed     Abstract available
    
    
    
57. DUAN Y, Gao H, Jin L, Yang J, et al
    Genetic and clinical characteristics of 54 pediatric lymphoma patients with variant mutation sites of UNC13D.
    Haematologica. 2026 Mar 5. doi: 10.3324/haematol.2025.287782.
    PubMed     Abstract available
    
    
    
58. YANG J, Villa D, Gerrie AS, Tonseth RP, et al
    Bleomycin omission in limited-stage classic Hodgkin lymphoma with negative PET scan after two cycles of ABVD.
    Haematologica. 2026 Mar 5. doi: 10.3324/haematol.2025.289285.
    PubMed     Abstract available
    
    
    
59. ABRISQUETA P, Karimi YH, Morillo D, Cordoba R, et al
    Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trial.
    Haematologica. 2026 Mar 5. doi: 10.3324/haematol.2025.300086.
    PubMed     Abstract available
    
    
    February 2026
60. KOCA O, Kucukyurt S, Eskazan AE
    Frontline therapy in primary mediastinal B-cell lymphoma: when salvage outcomes redefine the meaning of intensity. Comment on: Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R.
    Haematologica. 2026 Feb 26. doi: 10.3324/haematol.2026.000004.
    PubMed     Abstract available
    
    
    
61. KUCHNIO A, Yang D, Vloemans N, Cornelissen I, et al
    Characterization of JNJ-80948543 a novel CD79bxCD20xCD3 trispecific antibody for B-cell non-Hodgkin lymphoma.
    Haematologica. 2026 Feb 26. doi: 10.3324/haematol.2025.288473.
    PubMed     Abstract available
    
    
    
62. THARMASEELAN H, Sgonina LM, Buhnen I, Schnetzke U, et al
    Anti-programmed cell death protein 1-based salvage therapy for relapsed/refractory Hodgkin lymphoma: a multicenter real-world analysis.
    Haematologica. 2026 Feb 26. doi: 10.3324/haematol.2025.288996.
    PubMed     Abstract available
    
    
    
63. DANN EJ
    Is it time to reduce the doxorubicin dosage in Hodgkin lymphoma therapy?
    Haematologica. 2026 Feb 26. doi: 10.3324/haematol.2025.289210.
    PubMed     Abstract available
    
    
    January 2026
64. CASTONGUAY M, Seymour JF
    Transforming mantle cell lymphoma: the journey across eras.
    Haematologica. 2026 Jan 29. doi: 10.3324/haematol.2025.300275.
    PubMed     Abstract available
    
    
    
65. SIMONSEN MR, Eyre TA, Hawkes EA, El-Galaly TC, et al
    Older patients with lymphoma: navigating a landscape of clinical controversies and barriers to innovation.
    Haematologica. 2026 Jan 15. doi: 10.3324/haematol.2025.288700.
    PubMed     Abstract available
    
    
    
66. BES AL, Zwezerijnen GJC, Heymans MW, Duhrsen U, et al
    Improving the predictive value of end-of-treatment PET/CT in diffuse large B-cell lymphoma.
    Haematologica. 2026 Jan 8. doi: 10.3324/haematol.2025.288821.
    PubMed     Abstract available
    
    
    December 2025
67. MARCUS R, Avigdor A, Greenbaum U, Brown S, et al
    Locally manufactured versus commercial CAR T therapy for large B-cell lymphoma : a multi-center propensity score-matched analysis.
    Haematologica. 2025 Dec 24. doi: 10.3324/haematol.2025.288419.
    PubMed     Abstract available
    
    
    
68. LEE D, Dahiya S
    Mapping the immune orchestra of zamtocabtagene autoleucel in primary CNS lymphoma.
    Haematologica. 2025 Dec 24. doi: 10.3324/haematol.2025.289294.
    PubMed     Abstract available
    
    
    
69. TERAKAWA T, Fuji S, Shi H, Amemiya Y, et al
    Secondary T-cell lymphoma arising from pre-existing clones in a patient with diffuse large B-cell lymphoma during epcoritamab treatment following CAR-T therapy.
    Haematologica. 2025 Dec 24. doi: 10.3324/haematol.2025.289269.
    PubMed     Abstract available
    
    
    
70. KAMA K, Treiber H, Kutilina A, Trefz S, et al
    Rituximab, Dexamethasone, Etoposide, Ifosfamide and Carboplatin (R-DeVIC) in relapsed or refractory central nervous system lymphoma - a retrospective multicentre clinical study.
    Haematologica. 2025 Dec 11. doi: 10.3324/haematol.2025.287982.
    PubMed     Abstract available
    
    
    
71. SCHMIDT C, Scheubeck G, Jurinovic V, Sokler M, et al
    Erratum to: "Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance".
    Haematologica. 2025;110:3180-3181.
    PubMed    
    
    
    November 2025
72. OLSZEWSKI AJ, Ollila TA, Chihara D, Shouse G, et al
    Comparative effectiveness of immunotherapy alone or with chemotherapy as first-line treatment for marginal zone lymphoma.
    Haematologica. 2025 Nov 27. doi: 10.3324/haematol.2025.288946.
    PubMed     Abstract available
    
    
    
73. KIENER TA, Schweighofer-Zwink G, Rendl G, Kern JM, et al
    Complete remission of bronchus-associated lymphoid tissue lymphoma after antibiotic treatment for Tropheryma whipplei.
    Haematologica. 2025 Nov 27. doi: 10.3324/haematol.2025.288045.
    PubMed     Abstract available
    
    
    
74. JOFFE E, Uppal M, Zheng S, Bantilan KS, et al
    Mutational and copy number analysis at diagnosis and relapse of mantle cell lymphoma.
    Haematologica. 2025 Nov 27. doi: 10.3324/haematol.2024.286813.
    PubMed     Abstract available
    
    
    
75. RINGELSTEIN-HARLEV S
    Old methods, lasting impact in relapsed/refractory primary mediastinal B-cell lymphoma.
    Haematologica. 2025 Nov 13. doi: 10.3324/haematol.2025.289153.
    PubMed     Abstract available
    
    
    
76. LOH Z, Yeh P, Keane C, Hawkes EA, et al
    Advances in biomarkers for mantle cell lymphoma in the era of targeted therapies.
    Haematologica. 2025 Nov 6. doi: 10.3324/haematol.2025.288185.
    PubMed     Abstract available
    
    
    
77. PATEL J, Gopal A, Cherniawsky H, Ram R, et al
    CD19 directed CAR T therapy for intravascular large B-cell lymphoma.
    Haematologica. 2025 Nov 6. doi: 10.3324/haematol.2025.288838.
    PubMed     Abstract available
    
    
    October 2025
78. JIANG L, Ladetto M, Hermine O, Kluin-Nelemans JC, et al
    Marked survival gains in patients
    Haematologica. 2025 Oct 30. doi: 10.3324/haematol.2025.288929.
    PubMed     Abstract available
    
    
    
79. HESS B, Moskowitz A, Davis JA, Strati P, et al
    Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R.
    Haematologica. 2025 Oct 30. doi: 10.3324/haematol.2025.288232.
    PubMed     Abstract available
    
    
    
80. HARDY NM, Yared JA, Luetkens T, Ahmad H, et al
    CNS infiltration by zamtocabtagene autoleucel tandem CD20/CD19 CAR T cells leading to complete remission in a patient with primary CNS lymphoma.
    Haematologica. 2025 Oct 16. doi: 10.3324/haematol.2025.288856.
    PubMed     Abstract available
    
    
    
81. MARR KC, Tang T, Simkin J, Kim J, et al
    Long-term cardiac morbidity in adolescent and young adult survivors of classical Hodgkin lymphoma: the British Columbia experience.
    Haematologica. 2025 Oct 9. doi: 10.3324/haematol.2025.288058.
    PubMed     Abstract available
    
    
    
82. SENTHIL H, Streilein S, Whiteside T, Minuk L, et al
    Real-world safety and tolerability of rapid infusion obinutuzumab in chronic lymphocytic leukemia, small lymphocytic lymphoma and non-Hodgkin lymphoma: a provincial review.
    Haematologica. 2025 Oct 9. doi: 10.3324/haematol.2025.288780.
    PubMed     Abstract available
    
    
    
83. YANG J, Hayden AR, Villa D, Jiang A, et al
    Utility of the Central Nervous System International Prognostic Index in patients with primary mediastinal large B-cell lymphoma treated with rituximab-containing chemoimmunotherapy.
    Haematologica. 2025 Oct 2. doi: 10.3324/haematol.2025.288699.
    PubMed     Abstract available
    
    
    September 2025
84. CHUNG E, Wang L, Wellard C, Barraclough A, et al
    Prognostic value of tumor bulk in modern management of common lymphoma subtypes: an Australasian Lymphoma and Related Diseases Registry study.
    Haematologica. 2025 Sep 25. doi: 10.3324/haematol.2025.287919.
    PubMed     Abstract available
    
    
    
85. SANTORO A, Improta CM, Sarina B, Mannina D, et al
    Brentuximab vedotin plus nivolumab as bridging therapy to CAR T-cells in relapsed/refractory primary mediastinal B-cell lymphoma.
    Haematologica. 2025 Sep 18. doi: 10.3324/haematol.2025.287672.
    PubMed     Abstract available
    
    
    August 2025
86. MOLLA R, Bantilan K, Berman E, Caron P, et al
    Two decades of single-institution data reveal rare long-term survivors of relapsed/refractory Burkitt lymphoma.
    Haematologica. 2025 Aug 7. doi: 10.3324/haematol.2024.287165.
    PubMed     Abstract available
    
    
    July 2025
87. GHIONE P, Zinzani PL, Brown JR
    Lessons learned from experience of phosphatidylinositol 3-kinase inhibitors in chronic lymphocytic leukemia and lymphoma.
    Haematologica. 2025 Jul 24. doi: 10.3324/haematol.2025.288114.
    PubMed     Abstract available
    
    
    
88. MOSKOWITZ AJ
    Fit, unfit, or frail? Now easier to tell for Hodgkin lymphoma.
    Haematologica. 2025 Jul 17. doi: 10.3324/haematol.2025.288033.
    PubMed     Abstract available
    
    
    
89. IACCARINO I, Beder T, Reinke S, Borchmann P, et al
    Long non-coding RNA LINC00926 is a biomarker for naive B-cells with prognostic value in advanced stage classic Hodgkin Lymphoma.
    Haematologica. 2025 Jul 17. doi: 10.3324/haematol.2025.287524.
    PubMed     Abstract available
    
    
    
90. ALHOMOUD M, Ibrahim R, Demetres M, Rejeski K, et al
    Safety and efficacy of bridging radiation therapy prior to CD19 CAR T for non-Hodgkin lymphoma: a systematic review and meta-analysis.
    Haematologica. 2025 Jul 10. doi: 10.3324/haematol.2025.287547.
    PubMed     Abstract available
    
    
    
91. SHOUSE G, Chen C, Muir A, Popplewell L, et al
    Safety and efficacyof the combination of copanlisib and nivolumab in patients with Richter's transformation or transformed non-Hodgkin lymphoma: results from a phase I trial.
    Haematologica. 2025 Jul 3. doi: 10.3324/haematol.2024.286945.
    PubMed     Abstract available
    
    
    
92. DANILOV AV, Li H, Shadman M, Rimsza L, et al
    Minimal residual disease status predicts outcomes in patients with follicular lymphoma treated with chemo-immunotherapy on the SWOG S0016 trial.
    Haematologica. 2025 Jul 3. doi: 10.3324/haematol.2025.288057.
    PubMed     Abstract available
    
    
    
93. DOGLIOTTI I, Federico M
    BTKi +humanized anti-CD20 for advanced follicular lymphoma: ready for an ALTERNATIVE?
    Haematologica. 2025 Jul 3. doi: 10.3324/haematol.2025.288196.
    PubMed     Abstract available
    
    
    June 2025
94. ATALLAH-YUNES SA, Rees MJ, Habermann TM, Wang Y, et al
    Treatment approaches and clinical outcomes in primary colorectal MALT lymphoma: a single institution retrospective study of 66 patients.
    Haematologica. 2025 Jun 19. doi: 10.3324/haematol.2025.288145.
    PubMed     Abstract available
    
    
    
95. SCHMIDT C, Scheubeck G, Jurinovic V, Sokler M, et al
    Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance.
    Haematologica. 2025 Jun 12. doi: 10.3324/haematol.2024.287162.
    PubMed     Abstract available
    
    
    
96. LIA K, Jorgensen RRK, Wikman P, Wold BL, et al
    Response to Comment on: A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma.
    Haematologica. 2025 Jun 12. doi: 10.3324/haematol.2025.288284.
    PubMed     Abstract available
    
    
    
97. XAVIER AC, Liao Y, Cairo MS
    Persistent Epstein-Barr virus viremia in NK-/T-cell lymphoma: bad boys for life!
    Haematologica. 2025 Jun 5. doi: 10.3324/haematol.2025.287922.
    PubMed     Abstract available
    
    
    
98. HUANG K
    When 'simplified' may be oversimplified: reassessing frailty scoring in elderly Hodgkin lymphoma. Comment on: A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma.
    Haematologica. 2025 Jun 5. doi: 10.3324/haematol.2025.288186.
    PubMed     Abstract available
    
    
    
99. AUTIO M, Bruck O, Pollari M, Karjalainen-Lindsberg ML, et al
    Characterization of tumor microenvironment and cell interaction patterns in testicular and diffuse large B-cell lymphomas.
    Haematologica. 2025;110:1339-1350.
    PubMed     Abstract available
    
    
    May 2025
100. MAGNI M, Jonnalagadda S, Bonifazi F, Bonafe M, et al
     CAR T expansion and systemic inflammation: diverging impacts on large B-cell lymphoma therapy in the multicenter CART SIE study.
     Haematologica. 2025 May 29. doi: 10.3324/haematol.2025.287528.
     PubMed     Abstract available
     
     
     
101. DE GROOT FA, Stedema FG, Kret EJ, De Haan LM, et al
     MATRix and HD-MTX/IFO/DEP treatment and autologous stem cell transplantation in secondary central nervous system lymphoma: a Dutch retrospective analysis.
     Haematologica. 2025 May 29. doi: 10.3324/haematol.2025.287485.
     PubMed     Abstract available
     
     
     
102. ARDISSINO G, Angelillo P, Mancuso MC, Griffini S, et al
     Marginal zone lymphoma with anti-factor H IgM and atypical hemolytic uremic syndrome successfully treated with odronextamab.
     Haematologica. 2025 May 15. doi: 10.3324/haematol.2025.287532.
     PubMed     Abstract available
     
     
     
103. BRISOU G, Paillassa J, Bernard S, Tournilhac O, et al
     Clinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large Bcell lymphoma: real-world data from the EarlyMIND study.
     Haematologica. 2025 May 15. doi: 10.3324/haematol.2024.287141.
     PubMed     Abstract available
     
     
     
104. EERTINK JJ, Heymans MW, Wiegers SE, Bes AL, et al
     Risk prediction in diffuse large B-cell lymphoma improves when combining baseline PET features with interim PET response.
     Haematologica. 2025 May 15. doi: 10.3324/haematol.2024.287241.
     PubMed     Abstract available
     
     
     April 2025
105. SAITO M, Sato T, Hasegawa H, Tanabe K, et al
     Clonality analysis of HTLV-1-infected cells enhances prognostic precision in smoldering adult T-cell leukemia/lymphoma.
     Haematologica. 2025 Apr 30. doi: 10.3324/haematol.2025.287521.
     PubMed     Abstract available
     
     
     
106. LIA K, Jorgensen RRK, Wikman P, Wold BL, et al
     A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma.
     Haematologica. 2025 Apr 24. doi: 10.3324/haematol.2025.287509.
     PubMed     Abstract available
     
     
     
107. LI M, Zhang Y, Zong L, Zhang M, et al
     An oncolytic vaccinia virus expressing anti-CD47 nanobody exerts enhanced antitumor activity by mediating innate and adaptive immune cell infiltration and activation in the lymphoma tumor microenvironment.
     Haematologica. 2025 Apr 10. doi: 10.3324/haematol.2024.286923.
     PubMed     Abstract available
     
     
     
108. KIM TM, Lakhani NJ, Soumerai J, Kamdar M, et al
     Evorpacept plus rituximab for the treatment of relapsed or refractory non-Hodgkin lymphoma: results from the phase I ASPEN-01 study.
     Haematologica. 2025 Apr 10. doi: 10.3324/haematol.2024.286208.
     PubMed     Abstract available
     
     
     
109. ZHONG H, Cheng S, Xiong J, Chen J, et al
     Dynamic change in Epstein-Barr virus DNA predicts prognosis in early stage natural killer/T-cell lymphoma with pegaspargase-based treatment: long-term follow-up and biomarker analysis from the NHL-004 multicenter randomized study.
     Haematologica. 2025 Apr 10. doi: 10.3324/haematol.2025.287513.
     PubMed     Abstract available
     
     
     
110. IANNITTO E, Ferrero S, Bommier C, Drandi D, et al
     Erratum to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study.
     Haematologica. 2025;110:1048-1049.
     PubMed    
     
     
     
111. JACQUEMIN G, Granci V, Gallouet AS, Lalaoui N, et al
     Erratum to: Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin's lymphoma B cells.
     Haematologica. 2025;110:1047.
     PubMed    
     
     
     March 2025
112. IGLESIAS R, Diaz E, Fernandez S, Miguelez M, et al
     Clonal hematopoiesis is common in bone marrow of patients with classical Hodgkin lymphoma.
     Haematologica. 2025 Mar 20. doi: 10.3324/haematol.2024.286579.
     PubMed     Abstract available
     
     
     
113. PORTUGUESE AJ, Huang JJ, Jeon Y, Taheri M, et al
     Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow up.
     Haematologica. 2025 Mar 13. doi: 10.3324/haematol.2024.287010.
     PubMed     Abstract available
     
     
     
114. YAN M, Sethi S, Kumar J, Kumar A, et al
     Leukemic presentation in nodal mantle cell lymphoma is characterized by frequent SOX11 negativity, a poor risk genomic landscape including higher TP53 alterations, and worse overall survival.
     Haematologica. 2025 Mar 13. doi: 10.3324/haematol.2024.287108.
     PubMed     Abstract available
     
     
     
115. BOARDMAN AP, Gutgarts V, Flynn J, Devlin SM, et al
     Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapy.
     Haematologica. 2025;110:651-664.
     PubMed     Abstract available
     
     
     
116. GHOSH N, Sehgal A, Liu FF, Kostic A, et al
     Comparative efficacy of lisocabtagene maraleucel in the PILOT study versus second-line chemotherapy regimens in the real world.
     Haematologica. 2025;110:693-705.
     PubMed     Abstract available
     
     
     February 2025
117. ALVEY EN, Yap KL, Rathbun P, Fitzpatrick C, et al
     B-cell lymphoblastic leukemia/lymphoma with mutated IKZF1 N159Y: clinical and genetic features of an emerging entity.
     Haematologica. 2025 Feb 27. doi: 10.3324/haematol.2024.286626.
     PubMed     Abstract available
     
     
     
118. EL DAKER S, Qualls D, Derkach A, Beqaj S, et al
     Deep immunophenotypic dissection and clinical impact of T cells in the follicular lymphoma microenvironment.
     Haematologica. 2025 Feb 6. doi: 10.3324/haematol.2024.286383.
     PubMed     Abstract available
     
     
     
119. MINSON AG, Dickinson MJ
     New bispecific antibodies in diffuse large B-cell lymphoma.
     Haematologica. 2025 Feb 6. doi: 10.3324/haematol.2024.285343.
     PubMed     Abstract available
     
     
     
120. WILLSCHER E, Schultheiss C, Paschold L, Lea Schumann F, et al
     T-cell receptor architecture and clonal tiding provide insight into the transformation trajectory of peripheral T-cell lymphomas.
     Haematologica. 2025;110:457-469.
     PubMed     Abstract available
     
     
     January 2025
121. DOUGLAS G, Nicholls KM, Paul E, Loh Z, et al
     Opportunistic bone density assessment using pre-treatment [18F]FDG-PET/CT identifies fracture risk in lymphoma patients undergoing corticosteroid-containing chemotherapy.
     Haematologica. 2025 Jan 23. doi: 10.3324/haematol.2024.286618.
     PubMed     Abstract available
     
     
     
122. WENDLER J, Lewis RI, Kutilina A, Knott M, et al
     Pre-phase treatment with rituximab and high-dose methotrexate to re-evaluate eligibility for intensive induction treatment of frail patients with central nervous system lymphoma.
     Haematologica. 2025 Jan 23. doi: 10.3324/haematol.2024.286347.
     PubMed     Abstract available
     
     
     
123. HUGHES AD, Polonen P, Teachey DT
     Relapsed childhood T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma.
     Haematologica. 2025 Jan 9. doi: 10.3324/haematol.2024.285643.
     PubMed     Abstract available
     
     
     
124. SHAH NN, Wang M, Roeker LE, Patel K, et al
     Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial.
     Haematologica. 2025;110:92-102.
     PubMed     Abstract available
     
     
     
125. STEPHAN P, Perrot J, Voisin A, Barbery M, et al
     Deep phenotyping of nodal T-cell lymphomas reveals immune alterations and therapeutic targets.
     Haematologica. 2025;110:129-141.
     PubMed     Abstract available
     
     
     December 2024
126. SOSCIA R, Assanto GM, Starza ID, Moia R, et al
     Molecular measurable residual disease by immunoglobulin gene rearrangements on circulating tumor DNA predicts outcome in diffuse large B-cell lymphoma.
     Haematologica. 2024 Dec 19. doi: 10.3324/haematol.2024.286331.
     PubMed     Abstract available
     
     
     
127. DE MATTEIS S, Del Coco L, De Castro F, Giudetti AM, et al
     Metabolic profile evolution in relapsed/refractory B-cell non-Hodgkin lymphoma patients treated with CD19 chimeric antigen receptor T-cell therapy and implications in clinical outcome.
     Haematologica. 2024 Dec 19. doi: 10.3324/haematol.2024.285154.
     PubMed     Abstract available
     
     
     
128. BIEDERMANN A, Patra-Kneuer M, Mougiakakos D, Buttner-Herold M, et al
     Blockade of the CD47/SIRPalpha checkpoint axis potentiates the macrophage-mediated antitumor efficacy of tafasitamab.
     Haematologica. 2024;109:3928-3940.
     PubMed     Abstract available
     
     
     November 2024
129. NI V, Nasta SD, Barta SK, Schuster SJ, et al
     Identification of a clinicopathologic prognostic index for newly diagnosed large B cell lymphoma patients treated with R-CHOP.
     Haematologica. 2024 Nov 28. doi: 10.3324/haematol.2024.286560.
     PubMed     Abstract available
     
     
     
130. FALCHI L, Hutchings M, Carlo-Stella C, Morschhauser F, et al
     Dexamethasone is associated with reduced frequency and intensity of cytokine release syndrome compared with alternative corticosteroid regimens as premedication for glofitamab in patients with relapsed / refractory large B-cell lymphoma.
     Haematologica. 2024 Nov 28. doi: 10.3324/haematol.2024.286257.
     PubMed     Abstract available
     
     
     
131. ZELIKSON V, Gurumurthi A, Sawalha Y, Annunzio K, et al
     Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers.
     Haematologica. 2024 Nov 14:0. doi: 10.3324/haematol.2024.285977.
     PubMed     Abstract available
     
     
     
132. LEMONNIER F, Philippe G
     In T-follicular helper lymphomas, 'one lymphoma can hide another': beginning to explain.
     Haematologica. 2024 Nov 14. doi: 10.3324/haematol.2024.286173.
     PubMed     Abstract available
     
     
     
133. GRAINGER BT, Cheah CY
     "The End of the Golden Weather": therapeutic strategies for mantle cell lymphoma relapsed or refractory to covalent BTK inhibitors.
     Haematologica. 2024 Nov 14. doi: 10.3324/haematol.2024.286205.
     PubMed     Abstract available
     
     
     
134. BARON M, Labreche K, Veyri M, Desire N, et al
     Epstein-Barr virus and immune status imprint the immunogenomics of non-Hodgkin lymphomas occurring in immune-suppressed environments.
     Haematologica. 2024;109:3615-3630.
     PubMed     Abstract available
     
     
     October 2024
135. VALCARCEL B, Schonfeld SJ, Shiels MS, Castillo JJ, et al
     Survival outcomes in diffuse large B-cell lymphoma patients with and without HIV in the United States from 2001 to 2016: a population-based analysis.
     Haematologica. 2024 Oct 31. doi: 10.3324/haematol.2024.286343.
     PubMed     Abstract available
     
     
     
136. NIZAMUDDIN IA, Bartlett NL
     Bispecific antibodies in follicular lymphoma.
     Haematologica. 2024 Oct 31. doi: 10.3324/haematol.2024.285245.
     PubMed     Abstract available
     
     
     
137. BRIEGHEL C, Petersen SL, Brown PN, Niemann CU, et al
     Frequency of secondary T-cell lymphoma in chimeric antigen receptor Tcell naive B-cell lymphoid-lineage cancers is higher than that reported on chimeric antigen receptor T-cell therapy.
     Haematologica. 2024 Oct 17. doi: 10.3324/haematol.2024.286002.
     PubMed     Abstract available
     
     
     
138. ATALLAH-YUNES SA, Rees MJ, Witzig TE, Habermann TM, et al
     CODOX-M/IVAC-R versus DA-EPOCH-R in double hit/triple hit lymphoma patients aged 60 years or under.
     Haematologica. 2024 Oct 10. doi: 10.3324/haematol.2024.286168.
     PubMed     Abstract available
     
     
     
139. DOGAN A, Roshal M
     Challenges in defining the immune microenvironment in T-cell lymphoma.
     Haematologica. 2024 Oct 10. doi: 10.3324/haematol.2024.285836.
     PubMed     Abstract available
     
     
     
140. BAGGIO D, Cwynarski K
     Thiotepa-based autograft for primary central nervous system lymphoma.
     Haematologica. 2024;109:3083-3084.
     PubMed    
     
     
     
141. VALCARCEL B, Schonfeld SJ, Jackson SS, Dores GM, et al
     Changes in sex-specific incidence of lymphoid neoplasms across the lifespan.
     Haematologica. 2024;109:3408-3413.
     PubMed    
     
     
     
142. TARANTELLI C, Wald D, Munz N, Spriano F, et al
     Targeting CD19-positive lymphomas with the antibodydrug conjugate loncastuximab tesirine: preclinical evidence of activity as a single agent and in combination therapy.
     Haematologica. 2024;109:3314-3326.
     PubMed     Abstract available
     
     
     September 2024
143. GUAN X, Wang Y, Fang T, Wang J, et al
     Lymphoma cell-driven IL-16 is expressed in activated B-cell-like diffuse large Bcell lymphomas and regulates the pro-tumor microenvironment.
     Haematologica. 2024 Sep 26. doi: 10.3324/haematol.2024.285304.
     PubMed     Abstract available
     
     
     
144. CROCHET G, Houot R
     Comment to "Sequencing of cellular therapy and bispecific antibodies for the management of diffuse large B-cell lymphoma": chimeric antigen receptor T-cell therapy remains effective after exposure to bispecific antibodies.
     Haematologica. 2024 Sep 19. doi: 10.3324/haematol.2024.286353.
     PubMed     Abstract available
     
     
     
145. MERCADAL S, Ahn KW, Allbee-Johnson M, Ganguly S, et al
     Outcomes of patients with primary central nervous system lymphoma following CD19-targeted chimeric antigen receptor T-cell therapy.
     Haematologica. 2024 Sep 5. doi: 10.3324/haematol.2024.285613.
     PubMed    
     
     
     
146. LIN N, Sun X, Zhou H, Zou L, et al
     Loncastuximab tesirine in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma: a multicenter, open-label, single-arm, phase II trial.
     Haematologica. 2024 Sep 5. doi: 10.3324/haematol.2024.284973.
     PubMed     Abstract available
     
     
     
147. CASSANELLO G, Drill E, Rivas-Delgado A, Okwali M, et al
     Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experience.
     Haematologica. 2024 Sep 5. doi: 10.3324/haematol.2024.285600.
     PubMed     Abstract available
     
     
     
148. PHILLIPS T, Wang M, Robak T, Gallinson D, et al
     Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-naive or relapsed / refractory mantle cell lymphoma: phase Ib trial.
     Haematologica. 2024 Sep 5. doi: 10.3324/haematol.2023.284896.
     PubMed     Abstract available
     
     
     
149. SALVARIS RT, Allanson BM, Collins G, Cheah C, et al
     Nodular lymphocyte-predominant Hodgkin lymphoma: advances in disease biology, risk stratification, and treatment.
     Haematologica. 2024 Sep 5. doi: 10.3324/haematol.2024.285903.
     PubMed     Abstract available
     
     
     
150. URAK R, Pahlavanneshan S, Gittins B, Nakamura R, et al
     Simultaneous targeting of B-cell malignancies and human immunodeficiency virus with bispecific chimeric antigen receptor T cells.
     Haematologica. 2024;109:3053-3058.
     PubMed    
     
     
     
151. ALENCAR AJ, Alderuccio JP
     Not all central nervous system lymphomas are created equal.
     Haematologica. 2024;109:2769-2771.
     PubMed    
     
     
     August 2024
152. PILERI SA
     Entities versus diseases: Myers et al. propose distinct aspects of adult T-cell lymphoma/leukemia.
     Haematologica. 2024 Aug 29. doi: 10.3324/haematol.2024.286174.
     PubMed     Abstract available
     
     
     
153. HUANG D, Li F, Lin S, Xia J, et al
     A novel prognostic nomogram based on imaging and molecular parameters for newly diagnosed extranodal natural killer/T-cell lymphoma patients.
     Haematologica. 2024 Aug 15:0. doi: 10.3324/haematol.2024.285362.
     PubMed     Abstract available
     
     
     
154. RAVIKRISHNAN J, Diaz-Rohena DY, Muhowski E, Mo X, et al
     LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclax-resistant chronic lymphocytic leukemia.
     Haematologica. 2024 Aug 8. doi: 10.3324/haematol.2023.284353.
     PubMed     Abstract available
     
     
     
155. HILTON LK
     A nu mouse model of diffuse large B-cell lymphoma in constitutional Atm loss.
     Haematologica. 2024 Aug 8. doi: 10.3324/haematol.2024.285973.
     PubMed     Abstract available
     
     
     
156. MYERS CS, Williams E, Cornejo CB, Pongas G, et al
     Distinctive genomic features of human T-lymphotropic virus type 1-related adult T-cell leukemia-lymphoma in Western populations.
     Haematologica. 2024 Aug 8. doi: 10.3324/haematol.2024.285233.
     PubMed     Abstract available
     
     
     
157. EPSTEIN-PETERSON ZD, Drill E, Aypar U, Batlevi CL, et al
     Erratum to: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.
     Haematologica. 2024;109:2749-2752.
     PubMed    
     
     
     
158. MOSKOWITZ AJ
     Combination chemotherapy for Hodgkin lymphoma.
     Haematologica. 2024;109:2383-2384.
     PubMed    
     
     
     July 2024
159. HOLST JM, Pedersen MB, Enemark MB, Hansen MC, et al
     Co-shared genomic alterations within tumors from patients with both myeloproliferative neoplasms and lymphoma.
     Haematologica. 2024 Jul 25. doi: 10.3324/haematol.2023.283798.
     PubMed     Abstract available
     
     
     
160. MELODY M, Gordon LI
     Sequencing of cellular therapy and bispecific antibodies for the management of diffuse large B-cell lymphoma.
     Haematologica. 2024 Jul 18. doi: 10.3324/haematol.2024.285255.
     PubMed     Abstract available
     
     
     
161. GARGANO G, Vegliante MC, Esposito F, Pappagallo SA, et al
     A targeted gene signature stratifying mediastinal gray zone lymphoma into classical HL-like or PMBL-like subtypes.
     Haematologica. 2024 Jul 18. doi: 10.3324/haematol.2024.285266.
     PubMed     Abstract available
     
     
     
162. OTHMAN T, Frankel P, Allen P, Popplewell LL, et al
     Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphoma.
     Haematologica. 2024 Jul 18. doi: 10.3324/haematol.2024.285185.
     PubMed     Abstract available
     
     
     
163. WANG L
     Have we truly uncovered the key to primary vitreoretinal lymphoma's pathway to the central nervous system?
     Haematologica. 2024 Jul 11. doi: 10.3324/haematol.2024.286056.
     PubMed     Abstract available
     
     
     
164. SERNA A, Navarro V, Iacoboni G, Lopez L, et al
     Rituximab maintenance after bendamustine-based treatment for follicular lymphoma and mantle cell lymphoma may exert a negative influence on SARS-CoV-2 infection outcomes.
     Haematologica. 2024 Jul 11. doi: 10.3324/haematol.2024.285219.
     PubMed     Abstract available
     
     
     
165. DOURTHE ME, Auperin A, Rigaud C, Barbati M, et al
     Excellent outcome of children/adolescents with primary mediastinal large B-cell lymphoma treated with FAB/LMB-based chemotherapy regimen with rituximab.
     Haematologica. 2024 Jul 11. doi: 10.3324/haematol.2024.285403.
     PubMed     Abstract available
     
     
     
166. DE JONGE AV, Bruins WSC, Duetz C, Korst CLBM, et al
     Response to DA-EPOCH-R is associated with activation of 'fitter' cytotoxic T-cells in patients with newly diagnosed double and triple hit high-grade B-cell lymphoma.
     Haematologica. 2024 Jul 4. doi: 10.3324/haematol.2024.285170.
     PubMed     Abstract available
     
     
     
167. SALVINO MA, Domingo-Domenech E, Sureda A
     The importance of secondary cancer screening programs in Hodgkin lymphoma survivors.
     Haematologica. 2024 Jul 4. doi: 10.3324/haematol.2023.284609.
     PubMed     Abstract available
     
     
     
168. AL-SAWAF O
     High-risk stays high-risk: Bruton tyrosine kinase inhibitors in B-cell malignancies.
     Haematologica. 2024;109:2035-2037.
     PubMed    
     
     
     
169. SONG Y, Cao J, Zhang Q, Li C, et al
     Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors.
     Haematologica. 2024;109:2165-2176.
     PubMed     Abstract available
     
     
     June 2024
170. KASPRZYK ME, Sura W, Podralska M, Kazimierska M, et al
     Core regions in immunoglobulin heavy chain enhancers essential for survival of non-Hodgkin lymphoma cells are identified by a CRISPR interference screen.
     Haematologica. 2024 Jun 27. doi: 10.3324/haematol.2023.284672.
     PubMed     Abstract available
     
     
     
171. HERBAUX C, Bret C, Bachy E, Bories P, et al
     Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry.
     Haematologica. 2024 Jun 20. doi: 10.3324/haematol.2023.284786.
     PubMed     Abstract available
     
     
     
172. BENJAMINI O, Fried S, Shouval R, Flynn JR, et al
     Anti-CD19 chimeric antigen receptor T-cell therapy has less efficacy in Richter transformation than in de novo large B-cell lymphoma and transformed low-grade B-cell lymphoma.
     Haematologica. 2024 Jun 20. doi: 10.3324/haematol.2023.284664.
     PubMed     Abstract available
     
     
     
173. KAPHAN E, Bettega F, Vallet N, Fegueux N, et al
     PD-1 blockade and allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma, a matter of time: a national study on behalf of the Societe Francophone de Greffe de Moelle et de Therapie Cellulaire.
     Haematologica. 2024 Jun 13. doi: 10.3324/haematol.2024.284968.
     PubMed     Abstract available
     
     
     
174. CHENG J, Xi L, Jang Y, Kim J, et al
     An investigation of germline variants of HAVCR2 in subcutaneous panniculitis-like T-cell lymphoma and related lesions in a North American population.
     Haematologica. 2024 Jun 13. doi: 10.3324/haematol.2023.284738.
     PubMed     Abstract available
     
     
     
175. IZUMIYAMA K, Inao T, Goto H, Harada S, et al
     Event-free survival at 36 months is a suitable endpoint for diffuse large B-cell lymphoma patients treated with immunochemotherapy: real-world evidence from the North Japan Hematology Study Group.
     Haematologica. 2024 Jun 13. doi: 10.3324/haematol.2023.284841.
     PubMed     Abstract available
     
     
     
176. DAVIES N, Francis T, Oldreive C, Azam M, et al
     Genome-scale clustered regularly interspaced short palindromic repeats screen identifies nucleotide metabolism as an actionable therapeutic vulnerability in diffuse large B-cell lymphoma.
     Haematologica. 2024 Jun 6. doi: 10.3324/haematol.2023.284404.
     PubMed     Abstract available
     
     
     
177. YOSHIFUJI K, Sadato D, Toya T, Motomura Y, et al
     Impact of genetic alterations on central nervous system progression of primary vitreoretinal lymphoma.
     Haematologica. 2024 Jun 6. doi: 10.3324/haematol.2023.284953.
     PubMed     Abstract available
     
     
     
178. RAI S, Kim WS, Ando K, Choi I, et al
     Long-term efficacy and safety of tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: final analysis of phase IIb results.
     Haematologica. 2024 Jun 6. doi: 10.3324/haematol.2023.283992.
     PubMed     Abstract available
     
     
     May 2024
179. DANILOV AV, Flinn IW, Davids MS, Gregory B, et al
     The phase III DUO trial of PI3K inhibitor duvelisib versus ofatumumab in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final analysis including overall survival.
     Haematologica. 2024 May 30. doi: 10.3324/haematol.2024.285043.
     PubMed     Abstract available
     
     
     
180. GHIONE P, Salles G
     Spotlight on polatuzumab vedotin: new standards for diffuse large B-cell lymphoma?
     Haematologica. 2024 May 30. doi: 10.3324/haematol.2022.282362.
     PubMed     Abstract available
     
     
     
181. YADIGAROGLU K, Scharf S, Gretser S, Schafer H, et al
     Checkpoint inhibition enhances cell contacts between CD4+ T cells and Hodgkin-Reed-Sternberg cells of classic Hodgkin lymphoma.
     Haematologica. 2024 May 23. doi: 10.3324/haematol.2023.284512.
     PubMed     Abstract available
     
     
     
182. ELICE F, Sommaggio R, Cappuzzello E, Riva M, et al
     A rescue approach in refractory diffuse large B-cell lymphoma with obinutuzumab-redirected cytokine-induced killer cells: a first-in-human case report.
     Haematologica. 2024 May 9. doi: 10.3324/haematol.2023.284881.
     PubMed     Abstract available
     
     
     
183. RENAUD L, Wencel J, Pages A, Al Jijakli A, et al
     Nivolumab combined with brentuximab vedotin with or without mediastinal radiotherapy for relapsed/refractory primary mediastinal large B-cell lymphoma.
     Haematologica. 2024 May 2. doi: 10.3324/haematol.2023.284689.
     PubMed     Abstract available
     
     
     April 2024
184. LINK BK
     Follicular lymphoma treatment decisions: put GELF on the shelf?
     Haematologica. 2024 Apr 24. doi: 10.3324/haematol.2024.285286.
     PubMed     Abstract available
     
     
     
185. CAIRO MS
     TP3 binding domain mutations are bad news in Burkitt lymphoma.
     Haematologica. 2024 Apr 18. doi: 10.3324/haematol.2024.285213.
     PubMed     Abstract available
     
     
     
186. BOURLON C, Roddie C, Menne T, Norman J, et al
     Outcomes after chimeric antigen receptor T-cell therapy across large B-cell lymphoma subtypes.
     Haematologica. 2024 Apr 4. doi: 10.3324/haematol.2024.285010.
     PubMed     Abstract available
     
     
     
187. IKEDA D, Oura M, Uehara A, Tabata R, et al
     Prognostic relevance of tumor-infiltrating CD4(+) cells and total metabolic tumor volume-based risk stratification in diffuse large B-cell lymphoma.
     Haematologica. 2024 Apr 4. doi: 10.3324/haematol.2024.285038.
     PubMed     Abstract available
     
     
     March 2024
188. BI C, Huang Y, Ali R, Wang F, et al
     MYC overexpression in natural killer cell lymphoma: prognostic and therapeutic implications.
     Haematologica. 2024 Mar 28. doi: 10.3324/haematol.2023.283811.
     PubMed     Abstract available
     
     
     
189. PULCZYNSKI EJ, Simonsen MR, Kuittinen O, Fagerli UM, et al
     Elderly long-term survivors in the Nordic phase II study with first-line maintenance temozolomide for primary central nervous system lymphoma: a 10-year follow-up.
     Haematologica. 2024 Mar 28. doi: 10.3324/haematol.2024.285207.
     PubMed     Abstract available
     
     
     
190. WIGHT J, Blombery P, Lickiss J, Burgess M, et al
     Systemic diffuse large B-cell lymphoma involving the central nervous system have high rates of defective antigen presentation and immune surveillance.
     Haematologica. 2024 Mar 21. doi: 10.3324/haematol.2023.284600.
     PubMed     Abstract available
     
     
     
191. IANNITTO E, Ferrero S, Bommier C, Drandi D, et al
     Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study.
     Haematologica. 2024 Mar 14. doi: 10.3324/haematol.2023.284109.
     PubMed     Abstract available
     
     
     
192. ZHU ML, Drill E, Joffe E, Salles G, et al
     Validation of LymphGen classification on a 400-gene clinical next-generation sequencing panel in diffuse large B-cell lymphoma: real-world experience from a cancer center.
     Haematologica. 2024 Mar 14. doi: 10.3324/haematol.2023.284565.
     PubMed     Abstract available
     
     
     
193. TOLLEY ER, Lewinter C, Pedersen LM, Nielsen TH, et al
     Efficacy of intravenous high-dose methotrexate in preventing relapse to the central nervous system in R-CHOP(-like)-treated, high-risk, diffuse large B-cell lymphoma patients and its effect on mortality: a systematic review and meta-analysis.
     Haematologica. 2024 Mar 14. doi: 10.3324/haematol.2023.284281.
     PubMed     Abstract available
     
     
     
194. BARRACLOUGH A, Agrawal S, Talaulikar D, Chong G, et al
     Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study.
     Haematologica. 2024 Mar 7. doi: 10.3324/haematol.2023.284538.
     PubMed     Abstract available
     
     
     February 2024
195. DURAND R, Bellanger C, Kervoelen C, Tessoulin B, et al
     Selective pharmacologic targeting of CTPS1 shows single-agent activity and synergizes with BCL2 inhibition in aggressive mantle cell lymphoma.
     Haematologica. 2024 Feb 22. doi: 10.3324/haematol.2023.284345.
     PubMed     Abstract available
     
     
     
196. MARTIRE G, Lovisa F, Carraro E, Rizzato D, et al
     TP53 DNA binding domain mutational status and rituximab-based treatment are independent prognostic factors for pediatric Burkitt lymphoma patients stratification.
     Haematologica. 2024 Feb 22. doi: 10.3324/haematol.2023.284868.
     PubMed     Abstract available
     
     
     
197. STATHIS A, Pirosa MC, Orsucci L, Feugier P, et al
     IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma.
     Haematologica. 2024 Feb 22. doi: 10.3324/haematol.2023.283918.
     PubMed     Abstract available
     
     
     
198. YUAN X, Xie Y, Xu N, Liu H, et al
     Lenalidomide, rituximab, and methotrexate are effective in newly diagnosed primary central nervous system lymphoma.
     Haematologica. 2024 Feb 15. doi: 10.3324/haematol.2023.284834.
     PubMed     Abstract available
     
     
     
199. SAVAGE KJ, De Leval L
     Erratum to: Introduction to the peripheral T-cell lymphoma review series: advances in molecular characterization, classification refinement and treatment optimization.
     Haematologica. 2024;109:693-694.
     PubMed    
     
     
     
200. KUPPERS R
     Distinct t(14;19) translocation patterns in atypical chronic lymphocytic leukemia and marginal zone lymphomas.
     Haematologica. 2024;109:376-378.
     PubMed    
     
     
     
201. CARBO-MEIX A, Guijarro F, Wang L, Grau M, et al
     BCL3 rearrangements in B-cell lymphoid neoplasms occur in two breakpoint clusters associated with different diseases.
     Haematologica. 2024;109:493-508.
     PubMed     Abstract available
     
     
     January 2024
202. DESMARES A, Bouzy S, Thonier F, Goustille J, et al
     Hepatosplenic T-cell lymphoma displays an original oyster-shell cytological pattern and a distinct genomic profile from that of gamma-delta T-cell large granular lymphocytic leukemia.
     Haematologica. 2024 Jan 25. doi: 10.3324/haematol.2023.283856.
     PubMed     Abstract available
     
     
     
203. TUN AM, Wang Y, Maliske S, Micallef I, et al
     Autologous stem cell transplant in fit patients with refractory or early relapsed diffuse large B-cell lymphoma that responded to salvage chemotherapy.
     Haematologica. 2024 Jan 18. doi: 10.3324/haematol.2023.284704.
     PubMed     Abstract available
     
     
     
204. SAVAGE KJ, Slack GW
     Erratum to: DUSP22-rearranged ALK-negative anaplastic large cell lymphoma is a pathogenetically distinct disease but can have variable clinical outcome.
     Haematologica. 2024;109:365.
     PubMed    
     
     
     December 2023
205. SAVAGE KJ, De Leval L
     Introduction to the peripheral T-cell lymphoma review series: advances in molecular characterization, classification refinement and treatment optimization.
     Haematologica. 2023;108:3204-3210.
     PubMed    
     
     
     
206. LEWIS NE, Zhou T, Dogan A
     Biology and genetics of extranodal mature T-cell and NKcell lymphomas and lymphoproliferative disorders.
     Haematologica. 2023;108:3261-3277.
     PubMed     Abstract available
     
     
     
207. STUVER R, Epstein-Peterson ZD, Horwitz SM
     Few and far between: clinical management of rare extranodal subtypes of mature T-cell and NK-cell lymphomas.
     Haematologica. 2023;108:3244-3260.
     PubMed     Abstract available
     
     
     
208. BISIG B, Savage KJ, De Leval L
     Pathobiology of nodal peripheral T-cell lymphomas: current understanding and future directions.
     Haematologica. 2023;108:3227-3243.
     PubMed     Abstract available
     
     
     
209. NGU HS, Savage KJ
     Past, present and future therapeutic approaches in nodal peripheral T-cell lymphomas.
     Haematologica. 2023;108:3211-3226.
     PubMed     Abstract available
     
     
     
210. LACAN C, Caron J, Tarantino N, Fouquet B, et al
     CAR T-cell therapy for central nervous system lymphomas: blood and cerebrospinal fluid biology, and outcomes.
     Haematologica. 2023;108:3485-3490.
     PubMed    
     
     
     
211. ZHANG L, Zhu X, Qu W, Lu Y, et al
     Myeloid/lymphoid neoplasms associated with eosinophilia and rearrangements of PCM1::JAK2 with erythroblastic sarcoma: a case report and literature review.
     Haematologica. 2023;108:3506-3510.
     PubMed    
     
     
     November 2023
212. JALLOUK AP, Kui N, Sun R, Westin JR, et al
     Effect of delayed cell infusion in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy.
     Haematologica. 2023 Nov 30. doi: 10.3324/haematol.2023.284453.
     PubMed     Abstract available
     
     
     
213. MAURER MJ, Casulo C, Larson MC, Habermann TM, et al
     Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma.
     Haematologica. 2023 Nov 30. doi: 10.3324/haematol.2023.283737.
     PubMed     Abstract available
     
     
     
214. CARRAS S, Torroja A, Emadali A, Montaut E, et al
     Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.
     Haematologica. 2023 Nov 30. doi: 10.3324/haematol.2023.283724.
     PubMed     Abstract available
     
     
     
215. BROADBENT R, Crosbie P, Armitage CJ, Taylor B, et al
     Pilot study of lung cancer screening for survivors of Hodgkin lymphoma.
     Haematologica. 2023 Nov 16. doi: 10.3324/haematol.2023.283287.
     PubMed     Abstract available
     
     
     
216. HOFFMANN MS
     Routine consolidation of early stage primary bone lymphoma with radiation therapy does not improve outcomes.
     Haematologica. 2023 Nov 16. doi: 10.3324/haematol.2023.284303.
     PubMed     Abstract available
     
     
     
217. DE CONINCK S, De Smedt R, Lintermans B, Reunes L, et al
     Targeting hyperactive platelet-derived growth factor receptor-beta signaling in T-cell acute lymphoblastic leukemia and lymphoma.
     Haematologica. 2023 Nov 9. doi: 10.3324/haematol.2023.283981.
     PubMed     Abstract available
     
     
     
218. MAYR F, Kruse V, Fuhrmann DC, Wolf S, et al
     SH2 domain-containing inositol 5-phosphatases support the survival of Burkitt lymphoma cells by promoting energy metabolism.
     Haematologica. 2023 Nov 2. doi: 10.3324/haematol.2023.283663.
     PubMed     Abstract available
     
     
     
219. MAURER MJ
     The International Prognostic Index in aggressive B-cell lymphoma.
     Haematologica. 2023;108:2874-2879.
     PubMed    
     
     
     
220. LEIVONEN SK, Friman T, Autio M, Vaittinen S, et al
     Characterization and clinical impact of the tumor microenvironment in post-transplant aggressive B-cell lymphomas.
     Haematologica. 2023;108:3044-3057.
     PubMed     Abstract available
     
     
     October 2023
221. LIA K, Jorgensen RRK, L Wold B, Fluge O, et al
     Overall survival and causes of death in elderly patients with Hodgkin lymphoma: a Norwegian population-based case-control study.
     Haematologica. 2023 Oct 26. doi: 10.3324/haematol.2023.283721.
     PubMed     Abstract available
     
     
     
222. KUMAR A
     MYC overexpression: adding another piece to the puzzle of high-risk mantle cell lymphoma.
     Haematologica. 2023 Oct 19. doi: 10.3324/haematol.2023.284105.
     PubMed     Abstract available
     
     
     
223. REZAZADEH A, Szabo A, Khurana A, Inwards DJ, et al
     Outcomes of limited stage primary bone diffuse large B-cell lymphoma in the rituximab era: a multicenter, retrospective study.
     Haematologica. 2023 Oct 19. doi: 10.3324/haematol.2023.283210.
     PubMed     Abstract available
     
     
     
224. SONG YQ, Zhang HL, Huang HQ, Zhang QY, et al
     Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma.
     Haematologica. 2023 Oct 19. doi: 10.3324/haematol.2023.283802.
     PubMed     Abstract available
     
     
     
225. MEEUWES FO, Brink M, Plattel W, Van der Poel MWM, et al
     Outcome of combined modality treatment in first-line for stage I(E) peripheral T-cell lymphoma; a nationwide population-based cohort study from the Netherlands.
     Haematologica. 2023 Oct 5. doi: 10.3324/haematol.2023.283174.
     PubMed     Abstract available
     
     
     
226. CROSSWELL HE, LaCasce AS, Bartlett NL, Straus DJ, et al
     Brentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1.
     Haematologica. 2023 Oct 5. doi: 10.3324/haematol.2023.283303.
     PubMed     Abstract available
     
     
     
227. KAWATA T, Shimizu T, Shindo T, Fujiwara K, et al
     Tucidinostat restores CCR4 expression in adult T-cell leukemia/lymphoma.
     Haematologica. 2023 Oct 5. doi: 10.3324/haematol.2023.283266.
     PubMed     Abstract available
     
     
     
228. HO C, Smith SD
     More than a Lonca-shot: beating the odds in relapsed/refractory diffuse large B-cell lymphoma.
     Haematologica. 2023 Oct 5. doi: 10.3324/haematol.2023.284056.
     PubMed     Abstract available
     
     
     
229. PASTORCZAK A, Szmyd B, Braun M, Madzio J, et al
     Clinical and laboratory diversity of diffuse large B-cell lymphomas in children with Nijmegen breakage syndrome.
     Haematologica. 2023;108:2808-2813.
     PubMed    
     
     
     September 2023
230. KHANLARI M, Wang W, Liu YC, Wang L, et al
     Concurrent peripheral T-cell lymphoma and T-cell lymphoblastic leukemia/lymphoma with identical STIL::TAL1 fusion events.
     Haematologica. 2023 Sep 28. doi: 10.3324/haematol.2023.283585.
     PubMed     Abstract available
     
     
     
231. FLOWERS CR, Matasar MJ, Herrera AF, Hertzberg M, et al
     Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study.
     Haematologica. 2023 Sep 28. doi: 10.3324/haematol.2023.283557.
     PubMed     Abstract available
     
     
     
232. FEHNIGER TA, Watkins MP, Ezenwajiaku N, Wan F, et al
     A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma.
     Haematologica. 2023 Sep 14. doi: 10.3324/haematol.2022.282246.
     PubMed     Abstract available
     
     
     
233. ROSCHEWSKI M, Hodson DJ
     Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy.
     Haematologica. 2023 Sep 14. doi: 10.3324/haematol.2021.278613.
     PubMed     Abstract available
     
     
     
234. FUKANO R, Iijima-Yamashita Y, Iwafuchi H, Nakazawa A, et al
     Prognostic value of minimal disseminated disease assessed using digital PCR for 3'ALK assays in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
     Haematologica. 2023 Sep 7. doi: 10.3324/haematol.2023.282812.
     PubMed     Abstract available
     
     
     
235. LUMINARI S
     Prognostic tools for older patients with diffuse large B-cell lymphoma: complex patients require complex solutions and a personal touch.
     Haematologica. 2023;108:2269-2270.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum